Liver Cancer

Steatotic liver disease was associated with better liver function, lower recurrence rates, and improved overall survival in patients with liver cancer who received radiofrequency ablation.

Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial chemoembolization.

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers.

Through colon cancer and liver cancer, faith is what brought me to peace and clarity during treatment and now survivorship.

Patients can discuss minimally invasive robotic liver cancer surgery with their care teams. The process tends to be safe and effective, an expert said.

Even though I will never be cancer-free from cholangiocarcinoma, I’m ready to face the next chapter in my life and make the most of it.

Compared to open hemihepatectomy, the laparoscopic approach resulted in faster recovery time and higher quality of life, researchers found.

Jill May, B.S.N., RN, OCN, shows her commitment to her patients and their caregivers through acts of kindness and compassion — especially during tough times.

Adding Imfinzi and Avastin to transarterial chemoembolization led to a 23% reduction in the risk of progression or death in patients with liver cancer.

Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious side effects leading to regorafenib treatment discontinuation, researchers have found.

Keytrida plus Lenvima improved survival and duration of response in patients with advanced hepatocellular carcinoma.

Antiviral treatments play a crucial role in the survival of patients with either hepatitis B or C and liver cancer, but researchers have found that antiviral therapy is “severely underutilized” even among patients who undergo curative surgery.

In honor of Liver Cancer Awareness Month, CURE® highlighted some of the most impactful liver cancer developments from 2023.

Tislelizumab demonstrated similar overall survival and safety in unresectable hepatocellular carcinoma compared with Nexavar, research found.

Adding TPST-1120 to the standard of care for the treatment of unresectable or metastatic hepatocellular carcinoma, a type of liver cancer, improved progression-free survival and overall survival in a phase 1b/2 clinical study.

Using antidepressants after receiving a diagnosis of liver cancer may lower overall and cancer-specific mortality rates, according to recent research.

Rivoceranib plus Airuika demonstrates improvement for survival in patients with unresectable hepatocellular carcinoma, a subset of liver cancer.

Patients with unresectable hepatocellular carcinoma, a type of liver cancer, obtained a survival benefit over four years of follow-up with a treatment regimen of Imfinzi and Imjudo.

Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.

Patients with unresectable hepatocellular carcinoma treated with the STRIDE regimen, consisting of Imjudo and Imfinzi, experienced manageable immune-related side effects with improvements in overall survival.

Patients born outside of the U.S. may have improved liver cancer survival rates compared with U.S.-born patients, although more research is needed to determine what may be driving this effect, research showed.

TPST-1120 is displaying potential in combatting hepatocellular carcinoma, the fastest-rising cause of cancer-related death in the United States.

The use of ChatGPT (an artificial intelligence platform) tended to produce reliable cancer-related information in most circumstances, but patient-provider communication is still key, an expert said.

Patients with type 2 diabetes have an increased cancer burden and, as a result, a higher mortality rate, highlighting the importance of inflammatory factors like obesity and glucose control.

Patients with advanced HCC who progressed after treatment with immunotherapy may have a survival benefit when treated with second-line Lenvima.

Good science, along with creativity in applying and testing it properly, can be successful against all odds for patients with cholangiocarcinoma.

If approved by the FDA, zanidatamab could be the first HER-2 targeted therapy for patients with biliary tract cancers.

Biliary duct cancer, or cholangiocarcinoma, has always been known as a difficult-to-treat disease, but immunotherapies may make an impact on patients' lives.

The FDA approved Imjudo plus Imfinzi for advanced hepatocellular carcinoma, although more work is needed to develop a treatment that cures patients, an expert said.

The dual immunotherapy regimen of Imjudo and Imfinzi may provide patients with unresectable hepatocellular carcinoma a well-tolerated treatment to extend survival.